HK Stock Market Move | ANGELALIGN (06699) rose nearly 5%, with overseas business turning from loss to profit in the first half of the year. Morgan Stanley is optimistic about the company's strong sales momentum in both domestic and overseas markets.

ANGELALIGN (06699) rose nearly 5%, and as of the time of writing, it increased by 3.62% to HKD 98.7, with a transaction volume of HKD 60.62 million. Recently, ANGELALIGN disclosed its mid-term performance for 2026, reporting a total of 316,609 cases in the first half of the year, a year-on-year increase of 40.2%; revenue reached USD 231 million, representing a 42.9% year-on-year growth. According to the financial report, the total number of invisible orthodontic cases in the global market (excluding Mainland China) reached 168,000 in the first half of the year, marking a 43.4% year-on-year increase, with both case numbers and revenue contributions breaking the 50% mark. More critically, the overseas division has successfully turned around its previous losses, marking ANGELALIGN's successful establishment of a self-sustaining business model in overseas markets, officially transitioning from the exploration phase to the growth phase. On another front, in response to the numerous unmet demands for invisible orthodontics globally, the company continues to enhance its localized team and has hosted professional academic conferences such as iMaster and Angel Ascend in key markets including Europe, Asia-Pacific, North America, and Latin America, increasing doctor recognition of ANGELALIGN solutions and establishing a virtuous growth cycle led by professional academia worldwide. Morgan Stanley has released a research report adjusting ANGELALIGN's revenue forecast for 2026 to 2028, each increased by approximately 4% to reflect management's latest guidance on strong sales momentum in both China and overseas markets. The firm anticipates that the company's adjusted operating profit margin in its overseas business will continue to be profitable.